GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The aim of this trial is to study the safety, pharmacokinetics and preliminary efficacy of the HER2-targeted antibody-drug conjugate GQ1001 in combination with pyrotinib in patients with HER2-positive metastatic breast cancer patients who had failed previous anti-HER2 treatment.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18-75 lat
- •Potwierdzony histopatologicznie rak piersi HER2-dodatni (zaawansowany lub z przerzutami)
- •Poprzednie leczenie przeciwko HER2 (np. trastuzumab) nie przyniosło pożądanego efektu lub choroba powróciła
- •Co najmniej jeden widoczny guz do zmierzenia
- •Poprzednie leczenie taksanami
- •Sprawna funkcja serca, nerek i wątroby (badania laboratoryjne w normie)
- •Dobrze toleruje pacjent aktywności codzienne (stan ogólny 0-1)
- •Oczekiwana przeżywalność większa niż 3 miesiące
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- July 24, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Fudan University Shanghai Cancer Center
Shanghai, China
Trial contact
Biyun Wang
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/26/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.